In clinical practice cystatin C is known as a well-described serum marker of renal failure. At the same time cystatin C is becoming increasingly known marker of elevated risk of death from cardiovascular causes, myocardial infarction and stroke. Recent studies show that cystatin C is a strong and independent predictor of outcome at 12 months in acute heart failure (AHF). Moreover, cystatin C identifies patients with poor prognosis despite normal plasma creatinine.
HyTest offers a set of high-affinity monoclonal antibodies specific to different epitopes of human cystatin C molecule. HyTest provides also recommendation as best MAb combinations to be used in sandwich immunoassays for quantitative measurements of cystatin C in body fluids.